# REGENXBIO

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/regenxbio

- Industry: Biotechnology
- Headquarters: Rockville, US
- Website: www.regenxbio.com
- Total disclosed funding: $98M
- Latest round: Series D (May 15, 2015)
- Investors on record: 8

## About

REGENXBIO Inc. is a biotechnology company focused on developing innovative gene therapies using its NAV® Technology Platform to treat both common and rare diseases.Founded in 2008 in Rockville, US, REGENXBIO Inc. is dedicated to gene therapy development. The founders include Adam Hacking and Patrick Bradley, with Adam Hacking serving as CEO. The company raised USD 138.6 mn in its IPO on September 16, 2015, marking a significant funding milestone.REGENXBIO focuses on developing innovative gene therapy products aimed at addressing both common and rare diseases through its NAV® Technology Platform. The company’s core product candidates include ABBV-RGX-314, targeting retinal diseases; RGX-202, focused on Duchenne muscular dystrophy; and RGX-121, designed for treating MPS II (Hunter Syndrome). Each of these therapies employs adeno-associated virus (AAV) technology to deliver genetic material into patients' cells, potentially providing one-time curative treatments. The primary end-users of these therapies are patients suffering from the mentioned conditions, as well as their families, with a significant emphasis on improving their quality of life. REGENXBIO aims to expand its reach to both domestic and international markets, including regions across North America, Europe, and Asia, ensuring that its innovative solutions are accessible to patients in need around the globe.REGENXBIO's revenue model primarily revolves around partnerships and collaborations with larger pharmaceutical companies, facilitating the development and commercialization of its gene therapy products. The company reported revenue of USD 83.33 mn for the most recent year, 2024, with an EBITDA of USD -221.37 mn.REGENXBIO plans to utilize the funds from its 2015 IPO to support the launch of new gene therapy products, enhancing its portfolio. The company aims to expand into international markets, particularly targeting regions in Europe and Asia by 2025. Recent funding will facilitate these initiatives, enabling the development and commercialization of therapies such as ABBV-RGX-314 and RGX-202.

## Funding rounds

- Series D, May 15, 2015, $71M — Venrock, Vivo Capital, F-Prime Capital, Janus Henderson Investors, Jennison Associates, Deerfield Management, Brookside Capital
- Series C, Jan 23, 2015, $28M — Venrock, F-Prime Capital, Deerfield Management, Brookside Capital, FoxKiser

## Investors

- Venrock (https://capitalatlas.ai/funds/venrock) — Series C, Series D
- F-Prime Capital (https://capitalatlas.ai/funds/f-prime-capital) — Series C, Series D
- Deerfield Management (https://capitalatlas.ai/funds/deerfield-management) — Series C, Series D
- Brookside Capital — Series C, Series D
- FoxKiser — Series C
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series D
- Janus Henderson Investors — Series D
- Jennison Associates — Series D